ICARE Newsletter Winter 2021

Updates to National Comprehensive Cancer Network (NCCN) Guidelines Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Released September 8th, 2020:

Genetic testing criteria by cancer type:

Breast Cancer:

  • Broadened to include relatives with ALL grades of prostate cancer (not just high-grade)
  • Having multiple breast cancer diagnoses no longer depends on whether the diagnoses were on two different breasts

Prostate Cancer:

  • Now includes cribriform histology and ANY risk group (not just high-grade prostate cancer)
  • Only first-degree relatives should be offered genetic testing

Pancreatic Cancer:

  • Only first-degree relatives should be offered genetic testing

 

Released September 8th, 2020:

Breast cancer risk management recommendations by gene:

  • NBN: high-risk breast screening was removed as there is insufficient evidence to support high breast cancer risks
  • BARD1: added consideration for high-risk breast screening starting at age 40
  • RAD51C & RAD51D: risks for triple-negative breast cancer were broadened to include potential increase in female breast cancer risk
  • BRCA1/2: in men with gynecomastia, added consideration for annual mammogram at age 50 (or 10 years before earliest male breast cancer diagnosis in the family)

 

Released November 20th, 2020:
Inherited cancer gene tables expanded to include more detailed risk information, level of risk, and strength of evidence

Check out the full NCCN guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf




ICARE Social Media Post February 2020

Ovarian Cancer Risks in BRCA1/2

The risk of ovarian cancer is raised in women with BRCA1/2 mutations. Recent findings suggest that higher body mass index (BMI) may further raise the risk of ovarian cancer in premenopausal BRCA1/2 carriers.

Note that all women with BRCA1/2 mutations are at high risk for ovarian cancer, and should follow current National Comprehensive Cancer Network (NCCN) management guidelines which recommend risk-reducing salpingo-oophorectomy (removal of ovaries and fallopian tubes) between age 35 and 40 for BRCA1 carriers and between age 40 and 45 for BRCA2 carriers, regardless of BMI.

Check out the article at https://www.ncbi.nlm.nih.gov/pubmed/31213659 and NCCN guidelines by creating a FREE account at https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.